![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Cabotegravir and Rilpivirine As 2-Drug Oral Maintenance Therapy: LATTE W96 Results
|
|
|
Reported by Jules Levin
CROI 2015 Feb 23-26, Seattle, WA
David Margolis1, Sandy Griffith1, Marty St. Clair1, William Spreen1, Cynthia Brinson2, Graham Smith3, Jerome de Vente4, Debbie Hagins5, Kimberly Smith6, Peter Williams7
1 GlaxoSmithKline, Durham, North Carolina, United States;2 Central Texas Clinical Research, Austin, Texas, United States;3 Maple Leaf Medical Clinic, Toronto, Ontario, Canada;4 Living Hope Foundation, Long Beach, California, United States;5 Chatham County Health Department, Savannah, Georgia, United States;6 ViiV Healthcare, Durham, North Carolina, United States;7 Janssen Pharmaceuticals, Inc, Beerse, Belgium
![CROI1.gif](../images/030415/030415-3/CROI1.gif)
![CROI2.gif](../images/030415/030415-3/CROI2.gif)
![CROI3.gif](../images/030415/030415-3/CROI3.gif)
![CROI4.gif](../images/030415/030415-3/CROI4.gif)
![CROI5.gif](../images/030415/030415-3/CROI5.gif)
![CROI6.gif](../images/030415/030415-3/CROI6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|